Cellular senescence is increasingly regarded as a mechanism linking chronic tissue stress to persistent skin inflammation. Senescent cells are defined by stable cell-cycle arrest with remodeling of morphology, metabolism, and secretory phenotype, of which the senescence-associated secretory phenotype (SASP) is central. Because no single marker is sufficient, senescence in skin requires multiparameter, cell-type-resolved criteria. This Review addresses stress sensing, SASP induction, paracrine propagation, immune evasion, cellular heterogeneity, and therapeutic targeting, stratifying evidence by disease: chronic and diabetic wounds are best supported, whereas in psoriasis, atopic dermatitis, cutaneous lupus erythematosus, systemic sclerosis, and vitiligo the evidence remains largely associative, as SASP-like mediators overlap with cytokine programs from activated keratinocytes, stromal cells, and immune cells. Senescence-targeted interventions are classified as senolytics, senomorphics, or senopreventive/geroprotective strategies, and assessed at marker, SASP, senescent-cell-burden, and disease-outcome levels. It further notes that clinical translation depends on defining senescence-maintained lesion subtypes, establishing combinatorial biomarkers and spatial maps, and validating the efficacy and safety window of local therapies in suitable models and human tissues.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: